Qingdao Haier Biomedical Co Ltd
SSE:688139

Watchlist Manager
Qingdao Haier Biomedical Co Ltd Logo
Qingdao Haier Biomedical Co Ltd
SSE:688139
Watchlist
Price: 31.4 CNY -4% Market Closed
Market Cap: ¥9.9B

P/S

4.3
Current
8%
Cheaper
vs 3-y average of 4.6

Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.

P/S
4.3
=
Market Cap
¥10.8B
/
Revenue
¥2.3B

Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.

P/S
4.3
=
Market Cap
¥10.8B
/
Revenue
¥2.3B

Valuation Scenarios

Qingdao Haier Biomedical Co Ltd is trading below its 3-year average

If P/S returns to its 3-Year Average (4.6), the stock would be worth ¥33.99 (8% upside from current price).

Statistics
Positive Scenarios
3/4
Maximum Downside
-36%
Maximum Upside
+21%
Average Downside
1%
Scenario P/S Value Implied Price Upside/Downside
Current Multiple 4.3 ¥31.4
0%
3-Year Average 4.6 ¥33.99
+8%
5-Year Average 5.2 ¥37.98
+21%
Industry Average 4.4 ¥32.23
+3%
Country Average 2.8 ¥20.24
-36%

Forward P/S
Today’s price vs future revenue

Today's Market Cap Revenue Forward P/S
¥10.8B
/
Jan 2026
¥2.3B
=
4.3
Current
¥10.8B
/
Dec 2026
¥2.8B
=
3.9
Forward
¥10.8B
/
Dec 2027
¥3.2B
=
3.4
Forward
¥10.8B
/
Dec 2028
¥3.1B
=
3.5
Forward

Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.

Peer Comparison

All Multiples
P/S
P/E
All Countries
Close
Market Cap P/S P/E
CN
Qingdao Haier Biomedical Co Ltd
SSE:688139
10B CNY 4.3 39.8
US
Intuitive Surgical Inc
NASDAQ:ISRG
162.6B USD 16.1 56.9
US
Abbott Laboratories
NYSE:ABT
155.4B USD 3.4 24.8
US
Stryker Corp
NYSE:SYK
112.7B USD 4.5 34.7
IE
Medtronic PLC
NYSE:MDT
102.7B USD 2.9 22.3
US
Boston Scientific Corp
NYSE:BSX
83.8B USD 4.1 23.5
US
Edwards Lifesciences Corp
NYSE:EW
48.8B USD 7.7 44.5
DE
Siemens Healthineers AG
XETRA:SHL
39.3B EUR 1.7 18.6
US
IDEXX Laboratories Inc
NASDAQ:IDXX
45.2B USD 10.5 42.7
US
Becton Dickinson and Co
NYSE:BDX
42.5B USD 1.9 24.2
US
Resmed Inc
NYSE:RMD
29.9B USD 5.5 20.1

Market Distribution

In line with most companies in China
Percentile
63rd
Based on 7 736 companies
63rd percentile
4.3
Low
0 — 1.5
Typical Range
1.5 — 5.4
High
5.4 —
Distribution Statistics
China
Min 0
30th Percentile 1.5
Median 2.8
70th Percentile 5.4
Max 5 034 353.9

Qingdao Haier Biomedical Co Ltd
Glance View

Market Cap
9.9B CNY
Industry
Health Care

Qingdao Haier Biomedical Co Ltd, nestled within the vibrant hub of Qingdao, China, has been a dynamic player in the life sciences and healthcare industry since its inception. Originally part of the expansive Haier Group, known globally for its household appliances, Haier Biomedical has carved out a niche by focusing intently on the intersection of cold chain logistics and biomedical engineering. Its product line is built around the essential needs of the healthcare, pharmaceutical, and research sectors, where precise temperature control is not just an operational nicety but a critical necessity. The company's range of equipment—from ultra-low temperature freezers to blood bank refrigerators and smart cold storage solutions—acts as the backbone for preserving biological samples, vaccines, and medications. By pioneering smart technology integration within these systems, the company effectively meets stringent global standards, ensuring the safety and efficacy of conserved biological materials. The commercial success of Haier Biomedical stems from its dual strategy of deeply engaging with international markets while continuously innovating its product offerings. The company makes money by selling its high-tech storage and transport solutions to a vast array of clients including hospitals, research laboratories, and pharmaceutical manufacturers around the globe. This revenue model is bolstered by its ability to tap into an ever-growing demand for efficient biological storage, driven by global health initiatives and the rising importance of biotech advancements. Meanwhile, its continuous investment in R&D has positioned it as a leader in smart cold chain logistics, enabling it to adapt swiftly to the rapidly evolving landscape of global healthcare needs. By leveraging its technical expertise and maintaining strong relationships with sector stakeholders across the world, Haier Biomedical consistently achieves a robust financial performance, underpinned by its commitment to quality and innovation in the biomedical field.

Intrinsic Value
20.53 CNY
Overvaluation 35%
Intrinsic Value
Price ¥31.4
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett